Introduction
The scalp extends from the external occipital protuberance to the supraorbital margin. Anatomical characteristics include its stratifi ed structure (consisting of epidermis, dermis, subcutis, epicranial aponeurosis and the adjacent periosteum and skull) and the closely arranged adnexa (sebaceous glands, hair follicles, eccrine and apocrine glands) that are surrounded by a dense network of blood vessels and lymphatics. Said characteristics form the structural basis for the remarkably broad range of tumor types that may arise in this particular region, including over a hundred different neoplasms, hamartomas, malformations and cysts, both benign and malignant. Morphologically, a distinction is made between keratinocytic and melanocytic tumors, adnexal tumors, neoplasms of hematopoietic and lymphatic tissue, soft tissue tumors as well as neural tumors [ 1 ] . The growth pattern of these tumors is signifi cantly affected by the resistance to infi ltration caused by the scalp's stratifi ed structure. Given the site-specifi c vertical limitation created by the cranial bones, tumors therefore characteristically grow horizontally.
Although the incidence of tumors arising on the scalp is increased compared to those occurring elsewhere on the skin, these neoplasms are fortunately predominantly benign. Cysts constitute over 50 % of benign scalp tumors and primarily include trichilemmal, epidermoid and dermoid cysts; the estimated prevalence in the Western population is roughly 20 % [ 2 ] . Not least because of the high density of sebaceous glands, the scalp is the most common site of trichilemmal cysts, accounting for approximately 80 % of such lesions. There are numerous other benign scalp tumors such as lipoma, fi broma, pilomatricoma (calcifi ed cyst), seborrheic keratosis, nevi, hemangioma, warts and pseudolymphoma [ 3 ] .
Although the incidence of tumors arising on the scalp is increased compared to those occurring elsewhere on the skin, these neoplasms are fortunately predominantly benign.
While only approximately 1-2 % of all scalp tumors are malignant, they comprise up to 13 % of all malignant cutaneous neoplasms [ 4 ] . However, relevant epidemiologic data is sketchy. In one of the few more comprehensive studies, Chui et al. examined 398 Taiwanese patients with malignant scalp tumors. They found that, in terms of sheer frequency, basal cell carcinoma (41.2 %) and squamous cell carcinoma (16.6 %) were the most common lesions (as in our part of the world), with a peak incidence between 60 and 79 years, followed by metastases, adnexal tumors, angiosarcoma as well as lymphoma in decreasing order of prevalence [ 5 ] .
Against this complex background, the present article is intended to provide a concise overview of general principles and distinct features of the most important scalp tumors, without claiming to be exhaustive. The interested reader is referred to relevant publications.
Special characteristics of scalp tumors
Not only are scalp tumors characterized by an impressively broad and heterogeneous clinical spectrum, they frequently exhibit site-specifi c features that distinguish them from their counterparts elsewhere on the skin (Table 1 ) . Examples of these peculiarities will be discussed below.
Nonmelanoma skin cancer
Nonmelanoma skin cancer, predominantly basal cell carcinoma and squamous cell carcinoma, is the most common type of skin cancer among Caucasians, showing a continuously increasing incidence. Overall, 2-18 % of basal cell carcinomas and 3-8 % of squamous cell carcinomas are located on the scalp [ 4, 6, 7 ] . In this particular location, both tumors are clinically characterized by a greater tendency for ulceration. Thus, they more frequently present as chronic, non-healing ulcer, compared to elsewhere on the skin. Partly because squamous cell carcinomas of the scalp are often diagnosed at an advanced stage (which usually correlates with tumor diameter and depth of invasion), this location may be considered an independent risk factor (along with degree of differentiation and evidence of perineural infi ltration) for invasiveness, increased risk of recurrence and therefore a more unfavorable prognosis. However, this is not yet refl ected in current classifi cations, including the UICC (2009) and the AJCC (2011) classifi cation [8] [9] [10] [11] [12] [13] .
Basal cell carcinomas, too, recur more often on the scalp. In rare cases, they may even infi ltrate the cranium and dura (estimated incidence 0.03 %), especially when neglected or in case of particularly advanced disease [14] [15] [16] [17] . Compared to elsewhere on the skin, basal cell carcinomas of the scalp are more often nodular and also pigmented. Some cases therefore meet the clinical and dermoscopic criteria for a melanocytic lesion, which may render it diffi cult to distinguish them from melanoma. For example, dermoscopy of basal cell carcinomas in this location more often shows blue-gray ovoid nests, brown-black dots/globules, radial lines connecting to a common base, a blue-white veil and usually two or more melanocytic patterns at the same time [ 18, 19 ] .
Melanocytic scalp tumors
Clinical subtypes of melanocytic scalp lesions include common, papillomatous, congenital, blue, atypical and eclipse nevi (with central hypopigmentation). Dermoscopy usually shows a globular and globular-reticular pattern and prominent perifollicular hypopigmentation. Similar to melanocytic nevi of special sites (acral, While only approximately 1-2 % of all scalp tumors are malignant, they comprise up to 13 % of all malignant cutaneous neoplasms.
Not only are scalp tumors characterized by an impressively broad and heterogeneous clinical spectrum, they frequently exhibit site-specific features that distinguish them from their counterparts elsewhere on the skin.
Nonmelanoma skin cancer, predominantly basal cell carcinoma and squamous cell carcinoma, is the most common type of skin cancer among Caucasians, showing a continuously increasing incidence.
In this particular location, both tumors are clinically characterized by a greater tendency for ulceration. Thus, they more frequently present as chronic, non-healing ulcer, compared to elsewhere on the skin.
Similar to melanocytic nevi of special sites (acral, genital), there is an increased prevalence of histological features of dysplasia in scalp nevi.
genital), there is an increased prevalence of histological features of dysplasia in scalp nevi [ 20 ] .
Blue nevi , which usually present as fl at, blue-gray to blue-black pigmented lesions with a diameter of less than one centimeter, can grow to a size of several centimeters, especially the cellular variant. They are marked by an increased risk of malignant transformation, especially when there are mutations in the GNAQ and GNA11 gene. GNA11 -mutated blue nevi -similar to blue nevus-associated [ 21 ] . Three to six percent of primary melanomas are located on the scalp. Men are more frequently affected. Common types include superfi cial spreading, nodular and lentigo maligna melanoma with a high mitotic rate (> 3/mm). A more aggressive variant, desmoplastic melanoma, too, shows a predilection for the scalp (about 20 % of all cases) [ 22 ] (Figure 1 ). On dermoscopy, pigmented lesions in this location are characterized in particular by areas of regression and diffuse hypopigmentation. Histologically, they exhibit an average (Breslow) thickness of 2.4 mm (± 1.66) and show a tendency for ulceration, lymphovascular infi ltration and local recurrence. At the same time, the rate of positive regional sentinel lymph nodes (SLNs) is lower; however, this may also be attributed to false-negative SLN fi ndings. Potential reasons for the latter may include site-specifi c methodical limitations (more frequent extracervical location of SLNs), the presence of multiple nuchal/cervical SLNs or inability to detect them due to diffuse lymphatic drainage. Patients with undetectable SLNs are known to have a poorer prognosis compared with SLN-positive patients [23] [24] [25] . Scalp melanoma, which accounts for 10 % of melanoma-related deaths, generally has a poorer prognosis than melanoma at other sites. Studies suggest that it is not just the location itself that is a risk factor. Rather, the clinical and pathological triad of tumor thickness, SLN involvement and ulceration, which is less favorable overall on the scalp, has a major impact on overall survival. Lymph node metastases (in the form of micrometastases without lymphadenopathy occurring in 30 % of all patients [ 26 ] ), distant and, in particular, cerebral metastases are more common in patients with scalp melanoma [ 23, 24, [27] [28] [29] [30] [31] [32] .
Blue nevi are marked by an increased risk of malignant transformation, especially when there are mutations in the GNAQ and GNA11 gene. GNA11 -mutated blue nevi -similar to blue nevus-associated melanoma in general and melanoma mimicking cellular blue nevus -show a marked predilection for the scalp.
A more aggressive variant, desmoplastic melanoma, too, shows a predilection for the scalp (about 20 % of all cases). 
Adnexal tumors
Given that cutaneous adnexa are complex epithelial, myoepithelial and mesenchymal structures, the neoplasms originating therefrom are highly varied. Not surprisingly, about one in ten malignant scalp tumors is of adnexal origin [ 5 ] . They originate in hair follicles, sebaceous glands and more rarely in eccrine and apocrine sweat glands or their ducts. Thus, the histomorphological spectrum is broad. With the exception of eccrine glands, said structures originate from a common embryonic primordium, which not uncommonly leads to a single tumor exhibiting mixed differentiation ( Table 2 ) . Adnexal tumors can occur both sporadically and as part of rare genetic disorders such as Birt-Hogg-Dubé, Brooke-Spiegler, Cowden or Muir-Torre syndrome (Table 3 ) . Early occurrence -starting at puberty -of multiple monomorphic lesions in particular corroborates the clinical suspicion of a predisposing syndrome. Sporadic cases usually manifest themselves in the 5 th or 6 th decade [33] [34] [35] [36] . Clinically, benign adnexal tumors usually present as fi rm, elastic, non-ulcerated, skin-colored or erythematous/bluish and frequently hairless lesions of varying sizes (note: hair loss is an unfavorable sign). They typically remain asymptomatic for a long time and grow very slowly. On the other hand, rapid growth and ulceration, especially in elderly patients, raise the suspicion of malignancy or malignant transformation. In familial tumor syndromes, such alarm signs are often observed at a young age.
A (predominantly) benign adnexal tumor with a marked predilection for the scalp, proliferating trichilemmal cyst (PTC) primarily affects older women. It usually presents as a solitary nodulocystic lesion, measuring 1-10 cm, and is thought to originate from a preexisting trichilemmal cyst. Histologically, it may Clinically, benign adnexal tumors usually present as firm, elastic, non-ulcerated, skin-colored or erythematous/ bluish and frequently hairless lesions of varying sizes (note: hair loss is an unfavorable sign). They typically remain asymptomatic for a long time and grow very slowly. On the other hand, rapid growth and ulceration, especially in elderly patients, raise the suspicion of malignancy or malignant transformation. be diffi cult to make the distinction between PTC and squamous cell carcinoma as desmoplasia and/or proliferation of the epithelium into the cyst lumen may mimic pseudoinvasion. Trichilemmal keratinization, sharp demarcation, presence of a preexisting cyst and peripheral palisading are suggestive of PTC, whereas histological signs of malignancy include nuclear pleomorphism, increased mitotic activity, necrosis and ulceration [ 33, 35 ] . Virtually every benign adnexal tumor has a malignant counterpart. Though uncommon, given their aggressive local growth pattern and increased risk of lymph node (7.4 %) and distant metastasis (12.2 %), they are associated with a poor prognosis. The subgroup of malignant adnexal tumors has a 5-year overall and disease-specifi c survival rate of 73 % and 98 %, respectively [36] [37] [38] .
Characterized by infi ltrative local growth, high recurrence yet low metastatic rates, primary cutaneous adenoid cystic carcinoma also has a predilection for the scalp. So does mucinous eccrine carcinoma, which primarily occurs in elderly individuals. The latter frequently presents as a soft, non-ulcerated nodule that tends to recur; it metastasizes in 15-20 % of all cases. Given their overlapping characteristics, it is often challenging to make an unequivocal clinical and histological distinction between (primary) malignant adnexal tumors of the scalp and cutaneous metastases (for example, sebaceous carcinoma versus a breast cancer metastasis with sebaceous differentiation) [ 35, 39, 40 ] .
Merkel cell carcinoma
The scalp is one of the predilection sites for Merkel cell carcinoma (MCC), too. Compared with melanoma, this tumor -pathogenetically associated predominantly (> 80 %) both with UV radiation and with Merkel cell polyomavirus -is less common but has a higher mortality rate (> 15 %). The embryonic origin of Merkel cells remains subject to controversial debate. Initially, they were thought to originate in the neural crest, which is why MCC used to be classifi ed within the group of neuroendocrine tumors. Recent studies, however, point to an epidermal origin of these pale oval cells, which are located in the basal layer; the majority of Merkel cells are in close contact with sensory nerve endings [ 41 ] . Apart from ectodermal keratinocytes, it has also been suggested that mesodermal fi broblasts and even pre-/pro-B cells might be the origin of this tumor [ 42, 43 ] . While, unlike melanoma, a tumor thickness of less than 10 mm correlates only slightly with clinical stage and rate of metastasis, the primary location on the scalp is a distinct risk factor for larger MCCs associated with distant metastasis (8.7 %), which reduces the median survival to nine months. By comparison, the 5-year survival rate is 51 % for localized MCCs and 35 % in case of nodal involvement [44] [45] [46] .
Lymphomas
Even though the skin is (after the gastrointestinal tract) the second most common site of extranodal non-Hodgkin's lymphoma (NHL) (estimated incidence in the skin 1 in 100,000), scalp lymphomas are very uncommon [ 47 ] .
The most common B-cell lymphomas occurring on the scalp are primary cutaneous follicle center lymphoma and primary cutaneous marginal zone lymphoma, both of which have an excellent prognosis, with a 5-year survival rate of > 95 % and < 100 % respectively (Figures 2, 3 ) . In rare cases, primary cutaneous diffuse large B-cell lymphoma can present as a painless, slowly growing scalp tumor, associated with a poor prognosis and a median survival of two to fi ve years. Lymphoma cells can infi ltrate the cancellous bone (of the skull) and spread via communicating veins into Compared with melanoma, this tumor -pathogenetically associated predominantly (> 80 %) both with UV radiation and with Merkel cell polyomavirus -is less common but has a higher mortality rate (> 15 %).
While, unlike melanoma, a tumor thickness of less than 10 mm correlates only slightly with clinical stage and rate of metastasis, the primary location on the scalp is a distinct risk factor for larger MCCs associated with distant metastasis (8.7 %), which reduces the median survival to nine months. the soft tissues on both sides of the cranium. Progressive intracranial expansion subsequently leads to headaches, neurological defi cits and epileptic seizures [ 3, [48] [49] [50] . Among T-cell lymphomas, mycosis fungoides (predominantly with large-cell transformation) is the most common type occurring on the scalp, not rarely in the form of the prognostically more unfavorable folliculotropic variant (follicular papules; with/without mucin). Finally, primary cutaneous large-cell anaplastic lymphoma, with a good 10-year survival rate of approximately 90 %, also occurs in this region [ 51, 52 ] .
Sarcomas
Among the heterogeneous group of sarcomas, all of which are of mesenchymal origin, angiosarcoma in particular (1 % of all sarcomas) has a predilection for the scalp. Typical clinical features of this (usually sporadic) tumor are a highly aggressive course associated with a tendency for multifocal spread and early hematogenous dissemination. In the head region in particular, there is a high rate of local recurrences, even if the tumor was initially excised with wide (2-3 cm) surgical margins. Accordingly, the 5-year survival rate is only 10-30 %. Not infrequently is angiosarcoma initially diagnosed following a pneumothorax, which is due to its tendency for subpleural metastasis [ 53, 54 ] .
There have also been reports of liposarcoma arising on the scalp, with the myxoid subtype being the most common variant. Rapid growth and potential tissue necrosis can make it diffi cult to distinguish such a lesion from an infected benign trichilemmal cyst. It must also be borne in mind that the distinction between well-differentiated liposarcoma and lipoma using fi ne-needle aspiration or tissue biopsies may at times be challenging or even impossible [ 55 ] .
Metastases
The scalp's vascularity likely facilitates the relatively common occurrence of metastases in this region, predominantly from visceral tumors [ 56 ] . In women, over 70 % of metastases are attributable to breast cancer, followed by ovarian, lung, gastrointestinal and oropharyngeal cancer. In men, 10 % of metastases originate from the lung and gastrointestinal tract, followed (in decreasing frequency) by ENT/esophageal tumors and renal tumors [ 57 ] . Clinically, metastases typically present as highly indurated, indolent lesions. Alopecia neoplastica is a distinct, site-specifi c clinical presentation, which is usually caused by hematogenous breast cancer metastases. Tumor infi ltration and the infl ammation associated therewith lead to the destruction of hair follicles, clinically characterized by hair loss, indurated skin and telangiectasia.
Histological assessment of metastases always requires correlation with the primary tumor, given that different tumor types -especially on the scalp -can show morphological and immunohistochemical overlap with metastases originating from tumors of other organ systems [ 58 ] .
Pediatric scalp tumors
Pediatric scalp tumors are relatively rare and fortunately mostly (> 98 %) benign. Tumorous scalp lesions in this age group therefore predominantly have no neoplastic origin (Table 4 ) . In this context, lack of lesional mobility or a midline location should prompt an initial radiographic evaluation to rule out cranial (meningo-) encephalocele [ 59 ] .
Among T-cell lymphomas, mycosis fungoides (predominantly with large-cell transformation) is the most common type occurring on the scalp, not rarely in the form of the prognostically more unfavorable folliculotropic variant (follicular papules; with/without mucin).
Typical clinical features of this (usually sporadic) tumor are a highly aggressive course associated with a tendency for multifocal spread and early hematogenous dissemination. In the head region in particular, there is a high rate of local recurrences, even if the tumor was initially excised with wide (2-3 cm) surgical margins.
It must also be borne in mind that the distinction between well-differentiated liposarcoma and lipoma using fine-needle aspiration or tissue biopsies may at times be challenging or even impossible.
The scalp's vascularity likely facilitates the relatively common occurrence of metastases in this region, predominantly from visceral tumors.
Histological assessment of metastases always requires correlation with the primary tumor, given that different tumor types -especially on the scalp -can show morphological and immunohistochemical overlap with metastases originating from tumors of other organ systems.
Lack of lesional mobility or a midline location should prompt an initial radiographic evaluation to rule out cranial (meningo-)encephalocele.
With an incidence of 0.5-1 %, nevus sebaceus (NS) is among the most common benign scalp tumors in children. A complex hamartoma, NS is characterized -among other things -by sebaceous and sweat gland hyperplasia with absence of terminal hair follicles within the lesion. The lesion is caused by postzygotic mutations in the HRAS (95 % of cases) and KRAS genes (5 %), which also explains its linear arrangement along Blaschko's lines (mosaic RASopathy). While only about 1.7 % of pediatric sebaceous nevi give rise to -largely benign -tumors, approximately 10-30 % of adult cases are associated with complications in the form of syringocystadenoma, trichoblastoma or trichilemmoma (Figure 4 ) . Basal cell carcinoma (occurs in 3.5 % of all sebaceous nevi) and other malignant epithelial tumors such as malignant sebaceous gland carcinoma tend to be an exception in adults, too; female patients are predominantly affected [ 60 ] . Occasionally, sebaceous nevi Figure 4 Sebaceous nevus of the left temple in a 23-year-old patient presenting as characteristic waxy reddish-yellow papules; there is a nodular basal cell carcinoma arising in the medial aspect of the lesion.
are associated with various syndromes (including RASopathies) ( Table 3 ) . While prophylactic excision is not always necessary for the aforementioned reasons, prominent alopecia due to a sebaceous nevus may still be highly stigmatizing. Given the relatively small size of lesions during infancy, early surgical removal (usually associated with very good cosmetic outcomes) may therefore be considered in such cases [ 61 ] .
Pathogenetic principles of scalp tumors
UV exposure and reduced UV protection due to sparse hair (early childhood, [androgenetic] alopecia) or Fitzpatrick skin types I and II are considered the most important risk factors for developing (malignant) scalp tumors. Gender-specifi c differences in average hair length and in the incidence and clinical pattern of (e.g., androgenetic) alopecia with resultant differences in the intensity of cumulative UV exposure of the scalp also have an impact with respect to typical gender-related predilection sites for scalp tumors. According to Chiu et al., the frontal and vertex region are affected in women in particular, whereas men, who are more exposed overall, frequently develop lesions on the temples and in the postauricular and occipital regions; malignant scalp tumors are four times more common in men [ 5 ] . In addition, repeated contact with polycyclic hydrocarbons, chronic wounds, scars and human papillomaviruses (especially HPV types 16, 18 and 31) also promote the development of these malignant tumors [ 4, 62, 63 ] . Previous radiation therapy in the scalp region is also associated with an increased risk of malignant tumors. For example, the relative risk of basal cell carcinoma in particular is increased 3.6-fold (95 % CI) for those patients who were exposed to a cumulative dose of 4.8 Gy during radiation therapy for tinea capitis, which was popular in the fi rst half of the last century. Moreover, 40 % patients thus treated exhibit a more unfavorable multifocal growth pattern [ 64 ] .
There is a marked increase in the incidence of nonmelanoma skin cancer (NMSC) with age due to less effective immune surveillance; this also applies to immunosuppressed patients (including iatrogenic immunosuppression). For instance, about 70 % of Australian transplant recipients develop a squamous cell carcinoma within 20 years ( Figure 5 ) [ 65 ] . In addition, there is an increased risk of infi ltrative growth and tumor dedifferentiation. Although the mutation profi le UV exposure and reduced UV protection due to sparse hair (early childhood, [androgenetic] alopecia) or Fitzpatrick skin types I and II are considered the most important risk factors for developing (malignant) scalp tumors.
In addition, repeated contact with polycyclic hydrocarbons, chronic wounds, scars and human papillomaviruses (especially HPV types 16, 18 and 31) also promote the development of these malignant tumors.
There is a marked increase in the incidence of nonmelanoma skin cancer (NMSC) with age due to less effective immune surveillance; this also applies to immunosuppressed patients (including iatrogenic immunosuppression). is heterogeneous overall, UV signature mutations in p53 -, CDKN2A or Ras genes confi rm a direct correlation between UV exposure, DNA damage and skin carcinogenesis [ 13 ] . These kinds of mutations have been found in nonmelanoma skin cancer and atypical fi broxanthoma (AFX, dermal sarcoma). The latter is a rare mesenchymal tumor characterized by pseudosarcomatous proliferation of dermal fi broblasts. It has been classifi ed as a superfi cial variant of (the more invasive and aggressive) pleomorphic dermal sarcoma [ 66 ] .
Finally, photosensitizing genetic disorders and congenital DNA repair and immune defects (such as albinism, xeroderma pigmentosum) may predispose to a remarkably early occurrence of these epithelial malignancies [ 62 ] .
Diagnosis
Relatively frequently are scalp tumors diagnosed only at an advanced stage when they present as visible/palpable masses. Early detection is often rendered diffi cult because of the (dense) hair and the inaccessibility of certain regions to self-inspection. Tumors can therefore remain undetected for a prolonged period of time. For the same reasons, the patient's own account with regard to duration and changes in color and shape is less reliable. This circumstance underscores the importance of regular and thorough scalp exams. In this context, special training programs for certain professions such as hairdressers appears useful. Given that hairdressers regularly inspect the scalp of a large part of the population, they can detect suspicious lesions and thus play a key role in early diagnosis [ 67 ] .
Although most benign scalp tumors require surgical intervention only when they become infl amed or for cosmetic reasons, distinguishing them from malignant tumors purely on clinical grounds is often challenging or even impossible. In light of the astonishingly low rate of correct preoperative diagnoses as regards scalp tumors (13-27 %), indistinct and suspicious lesions should always warrant histological confi rmation [ 3 ] . For example, angiosarcoma can mimic numerous (more banal) skin conditions (hematoma, rosacea, erysipeloid, radiodermatitis) and should therefore always be considered in the differential diagnosis ( Figure 6 ) [ 53 ] . With respect to the interpretation of clinical symptoms, it should be noted that even histomorphologically benign scalp tumors may pose a differential diagnostic challenge. Given the limited space for expansion in this region, they can lead to compression and (early) infi ltration/erosion of neighboring structures, with associated symptoms such as facial swelling and proptosis. Initial clinical symptoms may therefore be misleading.
Noninvasive methods (such as dermoscopy and confocal laser microscopy) may also be useful in the (differential) diagnostic workup (as well as for follow-up, preoperative determination of tumor borders and assessment of excision margins) in the cosmetically delicate scalp region.
Non-neoplastic lesions must always be distinguished (Table 4 , Figure 7 ), given that tumors/tumorous lesions of the scalp may not only originate in the skin but (as noted above, especially in children) may also indicate an underlying process of the cranium or point to craniocephalic malformations ("tip of the iceberg"). Imaging studies such as ultrasound (index lesion, lymph nodes), CT (bone, lymph nodes), MRI (soft tissue, nerves) are important especially for large, hard immobile lesions, yet also for those with a midline location (e.g., subdural empyema, dermoid cyst). These tests help narrow down the differential diagnosis and determine the extent or depth of a given lesion (also during follow-up). Large congenital nevi (> 20 cm) and those associated with satellite nevi should be worked up for neurocutaneous melanocytosis (in 5-10 %) as soon as possible using cranial MRI, Relatively frequently are scalp tumors diagnosed only at an advanced stage when they present as visible/palpable masses. Early detection is often rendered difficult because of the (dense) hair and the inaccessibility of certain regions to self-inspection. Tumors can therefore remain undetected for a prolonged period of time.
In light of the astonishingly low rate of correct preoperative diagnoses as regards scalp tumors (13-27 %), indistinct and suspicious lesions should always warrant histological confirmation.
Non-neoplastic lesions must always be distinguished (Table 4 , Figure 7 ), given that tumors/tumorous lesions of the scalp may not only originate in the skin but (as noted above, especially in children) may also indicate an underlying process of the cranium or point to craniocephalic malformations ("tip of the iceberg"). especially if there are neurological symptoms (signs of increased intracranial pressure) [ 68, 69 ] . As regards the histological evaluation of scalp tumors, it should be borne in mind that non-mesenchymal lesions in this region frequently exhibit spindle-cell morphology (e.g., squamous cell carcinoma, [desmoplastic] melanoma) or pseudomalignant features; this phenomenon is artifi cially augmented in small, crushed biopsies. Given these micromorphological peculiarities, shave biopsies should be avoided to ensure that the tissue sample is as representative as possible [ 70 ] . Reliable and representative assessment of adnexal tumors in particular frequently requires complete excision as these lesions can present considerable diagnostic problems due to their morphological variety and essential clinicopathological overlap ( Table 2 ) .
If there is evidence of malignancy, current guidelines recommend a complete diagnostic workup including clinical examination (thorough skin exam, palpation of lymphatic drainage pathways/regional lymph nodes), imaging studies (ultrasound, CT/MRI, PET-CT) and possibly further biopsies, depending on the primary tumor type (see, for example, www.awmf.org , www.ado-homepage.de , www.eado.org , www.euroderm.org/edf ).
The signifi cance of sentinel lymph node biopsy (SLNB) for malignant scalp tumors remains unclear, not least because of the high rate of false-negative results (see above). Nevertheless, SLNB should be considered in the case of satellite and in-transit metastases and for melanomas with a Breslow thickness ≥ 0.8 mm [71] [72] [73] .
Treatment principles
Topical field therapy of early forms of nonmelanoma skin cancer Considered to be noninvasive squamous cell carcinomas in situ, actinic keratoses are among the most common early forms of malignant scalp tumors in everyday clinical practice; one in three patients over the age of 30 (seen by a dermatologist) is affected [ 74 ] . As regards the therapeutic approach to actinic keratoses, it has proven useful to make a distinction between the treatment of individual lesions and fi eld therapy; the latter is employed for multiple lesions or those with indistinct tumor borders. However, there is only limited qualitative evidence from studies comparing the effectiveness of the various treatment options available. In addition, response rates of 70-80 % contrast with high recurrence rates [ 75 ] . Given that certain one-time treatments are not suffi ciently effective (depending on extent, site, tolerability and compliance, among other things), it is important that methods employed for a longer period of time have a low side effect profi le. One of the classic modalities used for destroying localized and hypertrophic actinic keratoses and superfi cial basal cell carcinomas is cryotherapy. A relatively time-effi cient and inexpensive procedure, healing is often associated with hypopigmented scars [ 76 ] . Field therapy plays a signifi cant role especially for prevention as it allows for subclinical and incipient in situ carcinomas to be treated, thus preventing potential progression to invasive cancer [ 9, 77, 78 ] . Therapeutic agents include imiquimod, 5-fl uorouracil, diclofenac/hyaluronic acid and ingenol mebutate as well as conventional or daylight photodynamic therapy [ 75 ] . However, topical immunomodulators such as imiquimod may have a limited therapeutic effect in the scalp region, possibly because they cannot be applied as evenly due to the presence of hair [ 75, 79 ] . For the treatment of superfi cial basal cell carcinoma, the aforementioned topical agents (with the exception of imiquimod and conventional photodynamic therapy) are only available for off-label use; they should not be used for other basal cell carcinoma subtypes because of insuffi cient effi cacy [ 75 ] .
As regards the histological evaluation of scalp tumors, it should be borne in mind that non-mesenchymal lesions in this region frequently exhibit spindle-cell morphology (e.g., squamous cell carcinoma, [desmoplastic] melanoma) or pseudomalignant features; this phenomenon is artificially augmented in small, crushed biopsies.
If there is evidence of malignancy, current guidelines recommend a complete diagnostic workup including clinical examination (thorough skin exam, palpation of lymphatic drainage pathways/ regional lymph nodes), imaging studies (ultrasound, CT/MRI, PET-CT) and possibly further biopsies, depending on the primary tumor type.
For the treatment of superficial basal cell carcinoma, the aforementioned topical agents (with the exception of imiquimod and conventional photodynamic therapy) are only available for off-label use.
Primary excision
Excision of benign lesions is sometimes indicated for cosmetic and psychosocial reasons, if they cannot be unequivocally distinguished from malignant lesions, or if they become symptomatic, for instance by compressing other structures. In this context, for example, congenital nevi used to be surgically removed as soon as possible to reduce the allegedly increased melanoma risk. Today, however, a limited surgical approach is recommended [ 80, 81 ] . Surgical removal of congenital nevi up to 20 cm in size may be considered between the ages of one and two if surgically feasible, and mainly for cosmetic reasons, given the low overall risk of malignant transformation (0.1 % for nevi up to 10 cm in diameter and 1 % for nevi 10-20 cm in size). In addition, congenital nevi of the scalp usually tend to become lighter over time and thus cosmetically less bothersome, even though the infi ltration persists. However, (serial partial) excision is defi nitely indicated for all irregular and otherwise suspicious scalp lesions (for example, thick, nonhomogeneous nodular nevi) as follow-up is more diffi cult because of the hair [80] [81] [82] .
At any rate, surgical intervention is required if malignancy is clinically suspected or if there is deeper infi ltration or increased invasiveness (for example microcystic, sclerosing basal cell carcinoma). Clinical signs include induration, bleeding, increase in diameter, erythema, ulceration, hyperkeratosis, pruritus, pigmentation, pain).
Complete primary excision (with/without micrographic margin control), possibly followed by re-excision with tumor-specifi c surgical margins, is the treatment of choice for all malignant scalp tumors [ 8, 15, 17, 83 ] (Figure 8 ). Following excision, "simple" primary defect closure is preferable to more complex fl ap repairs because of the higher complication rates and greater subsequent diffi culty in determining the excision margins if the primary excision was incomplete [ 84 ] .
In this context, for example, congenital nevi used to be surgically removed as soon as possible to reduce the allegedly increased melanoma risk. Today, however, a limited surgical approach is recommended.
Complete primary excision (with/without micrographic margin control), possibly followed by re-excision with tumor-specific surgical margins, is the treatment of choice for all malignant scalp tumors. 
Strategies for local tumor control
Treatment options for inoperable tumors predominantly include radiation therapy and -increasingly -also electrochemotherapy. Using brief intense electric pulses, the latter involves the delivery of a chemotherapeutic agent such as bleomycin via electroporation directly into the (tumor) cells, where it achieves a high local concentration. This method is suitable for all inoperable yet accessible skin tumors such as squamous cell carcinoma, cutaneous metastases, Merkel cell carcinoma and angiosarcoma [ 85, 86 ] . In addition, there is an approved oncolytic tumor vaccine available for the treatment of advanced melanoma, which exerts both local and systemic anti-tumor effects [ 87 ] .
Systemic therapies
Systemic treatment options for locally advanced and metastatic tumors include immunotherapies (for example, PD-1 inhibitors for melanoma and Merkel cell carcinoma) and targeted molecular therapies based on the genetic tumor profi le. See current recommendations and guidelines issued by various scientifi c societies: www.awmf.org , www.ado-homepage.de , www.eado.org , www.euroderm.org/edf (Table 5 ) . To some extent, the latter have become routinely available for certain tumors (for example, melanoma, basal cell carcinoma, dermatofi brosarcoma protuberans). Classic cytotoxic chemotherapies continue to be used, largely for palliation. Given the complexity of these tumors, which often require multidisciplinary expertise, treatment regimens should be agreed on in a quality-assured manner and always involve an interdisciplinary tumor board.
Prevention
Irrespective of improvements and the increase in treatment options in recent years, preventive measures (UV avoidance [textile, chemical and physical UV protection], consistent follow-up for early detection of recurrence) continue to be critically important. Raising public awareness for this issue remains a key task of our specialty.
Prognosis
Malignant scalp tumors are generally characterized by a more aggressive biological behavior than their counterparts at other sites. Basal cell and squamous cell carcinoma, angiosarcoma and dermatofi brosarcoma protuberans, as well as Merkel cell carcinoma, microcystic adnexal carcinoma, metastases, melanoma and, in children, rhabdomyosarcoma have considerable destructive potential and are associated with signifi cant complications due to infi ltration/invasion of the periosteum, bone, dura and brain [ 17, 31, 88 ] . The risk of osseous infi ltration correlates with disease duration and tumor size, prior therapies (radiation therapy) and (aggressive) histological growth pattern (for example, sclerosing, micronodular, metatypical basal cell carcinoma) [ 15, 89 ] .
Factors that potentially have a negative effect on prognosis not only include the often-advanced age of the patients (comorbidities, "surgical resilience"), but also the inherently limited accessibility for surgery and radiation therapy. This is the reason why -in the scalp region -local tumor control is considered prognostically more signifi cant overall than the tumor-specifi c potential for metastasis [ 90, 91 ] .
Treatment options for inoperable tumors predominantly include radiation therapy and -increasingly -also electrochemotherapy. Using brief intense electric pulses, the latter involves the delivery of a chemotherapeutic agent such as bleomycin via electroporation directly into the (tumor) cells, where it achieves a high local concentration.
Systemic treatment options for locally advanced and metastatic tumors include immunotherapies (for example, PD-1 inhibitors for melanoma and Merkel cell carcinoma) and targeted molecular therapies based on the genetic tumor profile. Abbr.: Ab, antibody; T-VEC, talimogene laherparepvec; EGFR, epidermal growth factor receptor; PDGRF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; ECP, extracorporeal photopheresis [95] [96] [97] .
Conclusion
An interdisciplinary approach is desirable in the management of scalp tumors, given the complex and delicate location as well as the variety of clinical and morphological manifestations and the diagnostic and therapeutic challenges associated therewith. This must be emphasized all the more as independent care of patients with rare scalp tumors by various medical specialties (such as pediatrics, dermatology, plastic and neurosurgery, ENT or ophthalmology), which has been common practice, limits the generation of individual expertise and comprehensive data collection. However, such epidemiological data is necessary for reliable conclusions to be drawn about the incidence of these tumors and possible pathogenetic factors.
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